J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

On track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy manufacturing expansion.